LIF and gastric cancer: While the JAK1/STAT3 pathway was concomitantly activated in response to LIF, experiments performed with JAK1 inhibitor Ruxolitinib showed that the JAK1/STAT3 pathway was not involved in the LIF-mediated anti-tumorigenic effect in GC.